Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

Novo Nordisk now has an Ozempic pill. Citing a Novo spokesperson, pharmaceuticals news site BioPharmaDive reported yesterday ...

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout ...

Despite the current downward trend, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 ...

The MOU marks a significant step in strengthening the Kingdom’s healthcare sector and pharmaceutical manufacturing ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of its weight loss blockbuster “earlier this year,” according ...

Novo Nordisk (NYSE: NVO), the Danish drugmaker ... and Drug Administration an application to approve an oral form of its semaglutide GLP-1 weight loss drug. BioPharmaDive notes that Novo has ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.